ASH: No­var­tis rolls out ear­ly da­ta for a pair of 'sec­ond-gen' CAR-Ts with more pro­duc­tive cells de­liv­ered faster

The cur­rent gen­er­a­tion of cell ther­a­pies has proven a game chang­er in terms of treat­ing ag­gres­sive blood can­cers, but the tech has its lim­i­ta­tions. No­var­tis, one of the big­gies in the cur­rent gen­er­a­tion of these drugs, is now tak­ing lessons learned from CAR-T Kym­ri­ah to su­per­charge a “sec­ond-gen­er­a­tion” of CAR-Ts putting su­pe­ri­or cells in­to pa­tients faster.

No­var­tis on Mon­day rolled out ear­ly Phase I da­ta for a pair of au­tol­o­gous CAR-T cell ther­a­pies de­vel­oped through the drug­mak­er’s T-Charge plat­form, a process de­signed to pro­mote T cell “stem­ness” — a mea­sure of a cell’s abil­i­ty to self-re­new — by cut­ting man­u­fac­tur­ing times and spurring cell pro­lif­er­a­tion pri­mar­i­ly in pa­tients’ lymph nodes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER